In a mouse model of acute myeloid leukemia (AML), in vivo RNAi screening identified that the circadian rhythm genes (Bmal1 and Clock) are required for AML cell growth, and targeting the circadian machinery showed therapeutic effects by depleting leukemia stem cells and impaired cell proliferation (Puram et al., 2016). This evidence concerns the gene BMAL1 and acute myeloid leukemia.